UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

GT Biopharma Inc (GTBP)

GT Biopharma Inc (GTBP)
2.28 unch (-0.08%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime - - (-) -
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
2.28
Day High
2.32
Open 2.30
Previous Close 2.28 2.28
Volume 10,900 10,900
Avg Vol 14,615 14,615
Stochastic %K 35.98% 35.98%
Weighted Alpha -45.68 -45.68
5-Day Change +0.01 (+0.44%) +0.01 (+0.44%)
52-Week Range 1.72 - 10.66 1.72 - 10.66
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,788
  • Shares Outstanding, K 2,536
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,160 K
  • EBIT $ -14 M
  • EBITDA $ -14 M
  • 60-Month Beta 1.31
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.64
  • Number of Estimates 1
  • High Estimate -0.64
  • Low Estimate -0.64
  • Prior Year -2.12
  • Growth Rate Est. (year over year) +69.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.10 +8.54%
on 04/01/25
Period Open: 2.36
2.50 -8.80%
on 03/27/25
-0.08 (-3.39%)
since 03/25/25
3-Month
2.01 +13.43%
on 01/31/25
Period Open: 2.42
3.12 -26.92%
on 02/25/25
-0.14 (-5.79%)
since 01/24/25
52-Week
1.72 +32.56%
on 12/20/24
Period Open: 3.75
10.66 -78.61%
on 05/20/24
-1.47 (-39.23%)
since 04/25/24

Most Recent Stories

More News
GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit

GTBP : 2.28 (-0.08%)
GT Biopharma Retail Chatter Soars Most Among Biotechs After Financing Strategy Tweak

The company said it had withdrawn its earlier Form S-1 registration, initially filed with the SEC in December, which sought approval for an automatic mixed securities shelf offering.

VXF : 170.00 (+0.27%)
GTBP : 2.28 (-0.08%)
GT Biopharma Announces Exercise of Warrants

GTBP : 2.28 (-0.08%)
GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement

GTBP : 2.28 (-0.08%)
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies

GTBP : 2.28 (-0.08%)
GT Biopharma Reports Third Quarter 2024 Financial Results

GTBP : 2.28 (-0.08%)
GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update

Presented preclinical data demonstration second-generation CD19 targeting Tri-specific Killer Engager (TRIKE®) driving robust NK cell function against B...

GTBP : 2.28 (-0.08%)
GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress

Ongoing experiments will evaluate the functionality and efficacy of GTB-7550 in vivoFuture studies will also involve assessments of GTB-7550 TriKE efficacy...

GTBP : 2.28 (-0.08%)
GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update

Presented pre-clinical data at American Association for Cancer Research (AACR 2022), demonstrating GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer...

GTBP : 2.28 (-0.08%)
GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022

- Ongoing experiments will evaluate the functionality and efficacy of the B7H3 TriKE in vivo- Future studies will also involve assessments of the B7H3...

GTBP : 2.28 (-0.08%)

Business Summary

GT Biopharma Inc. is an immuno-oncology company. It discovers, develops and commercializes drugs of therapeutic molecules for the treatment of cancer, myeloma, osteolytic lesions and other unmet medical needs. GT Biopharma Inc., formerly known as OXIS International Inc., is based in Tampa, Florida.

See More

Key Turning Points

3rd Resistance Point 2.35
2nd Resistance Point 2.33
1st Resistance Point 2.31
Last Price 2.28
1st Support Level 2.27
2nd Support Level 2.25
3rd Support Level 2.23

See More

52-Week High 10.66
Fibonacci 61.8% 7.24
Fibonacci 50% 6.19
Fibonacci 38.2% 5.14
Last Price 2.28
52-Week Low 1.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective